References
- Childers MK: Use of Botulinum toxin Type A in pain management. Columbia, MO, AIS, Inc., 1999.
- Fischer AA: New developments in diagnosis of myofascial pain and fibromyalgia. Phys Med Rehabil Clin North Am 8:1-21,1997.
- Fischer AA: New approaches in treatment of myofascial pain. Phys Med Rehabil Clin North Am 8:153-169,1997.
- Gunn CC, Milbrandt WE, Little AS, et al: Dry needling of muscle motor points for chronic low back pain: A randomized clinical trial with longterm follow-up. Spine 5:279-291, 1980. https://doi.org/10.1097/00007632-198005000-00011
- Hackett GS: Ligament and tendon relaxation treated by prolotherapy, ed 3. Springfield, III, Thomas, 70:27-36, 1958.
- Imamura ST, Fischer AA, Imamura M, Teixeira MJ, Lin TY, Kaziyama US, Azze RJ and Amatuzzi MM: Pain management using myofascial approach when other treatment failed. Phys Med Rehabil Clin North Am 8:179-196, 1997.
- Mense S: Pathophysiologic basis of muscle pain syndromes. Phys Med Rehabil Clin North Am 8:23-53, 1997.
- Russell IJ: Neurochemical pathogenesis of fibromyalgia syndrome. Journal of Musculoskeletal painl:61-92, 1996.
- Russell IJ: Fibromyalgia syndrome diagnosis, pathogenesis, and management. Phys Med Rehabil Clin North Am 8:213-226,1997.
- Schwartz LL and Tausig DP: Temporomandibular joint pain - treatment with intramuscular infiltration of tetracaine hydrochloride: a preliminary report. NY State Dent J 20:219-223, 1954.
- Simons DG: Clinical and etiological update of myofascial pain from trigger points. Journal of Musculoskeletal pain4:93-121, 1996. https://doi.org/10.1300/J094v04n01_07
- Wolfe F, Ross K, Anderson J, et al: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19-28, 1995. https://doi.org/10.1002/art.1780380104